A Case Study of Characteristics and Means of Person-to-Person Influence in American Kodály Music Education: Katinka Scipiades Dániel

The purpose of this study was to investigate the characteristics and means of Katinka Dániel's interpersonal influences through the perceptions of 20 selected students, protégés, and colleagues, and to study the behavioral and attitudinal changes they attributed to her influence. A case study design and structured interview questionnaire were used to study four variables coming from the social sciences' literature on influence: legitimate authority, attractiveness, expert authority, and trustworthiness. Responses were qualitatively analyzed to determine the role those variables played in Dániel's interpersonal influence. All interviewees were music teachers who used the Kodály method in their teaching and have studied or worked with Dániel. Two images of Dániel emerged from the interviews. The first, a business-like image, emanated from Dániel's work in the classroom, and the second, a maternal image, came from personal relationships with her students and associates. Attractiveness (defined as a willingness to respond positively to the requests of an influential person because one respects that individual and wants to obtain that person's approval) proved to be the principal characteristic of influence, followed by legitimate authority, then expertise. Trustworthiness played a lesser role. The greatest effect of Dániel's influence was on the interviewees' teaching. Among the factors interviewees described as influential were her expectation they would succeed, her position as role model, praise and encouragement, and gestures of generosity and concern. Interviewees were not in agreement as to whether she used persuasion or coercion. Direct verbal communication served a principal role in Dániel's influence, and though her criticism was described as forthright and bluntly honest, interviewees often accepted it. This was because most believed she was focused on their best interest, because her motives were not considered self-serving, and because they saw the reasons for her criticism as stemming from her high ideals and the desire to see them improve as teachers. The dissertation includes a biography of Dániel

A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease

A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.BackgroundWe prospectively evaluated 3 treatment regimens of argatroban, a direct thrombin inhibitor, for providing adequate, safe anticoagulation in patients with end-stage renal disease (ESRD) during hemodialysis.MethodsIn this randomized, 3-way crossover study, ESRD patients underwent hemodialysis sessions of 3- or 4-hour duration using high-flux membranes and each of 3 argatroban treatment regimens (A: 250-μg/kg bolus, with an additional 250-μg/kg bolus allowed; B: 250-μg/kg bolus followed by 2-μg/kg/min infusion; C: steady-state, 2-μg/kg/min infusion initiated 4 hours before dialysis). Pharmacodynamic effects including activated clotting times (ACTs); hemodialysis efficacy including single-pool Kt/V, urea reduction ratio (URR), and circuit flow; and safety through a 3-day follow-up were monitored. Argatroban pharmacokinetic parameters including dialytic clearance were evaluated during regimen C.ResultsThirteen patients completed 38 hemodialysis sessions (1 patient withdrew consent after 2 sessions). Mean ± SD ACTs increased from 131 ± 14 seconds at baseline to 153 ± 24, 200 ± 30, and 197 ± 33 seconds, respectively, after 60 minutes of hemodialysis using regimens A, B, and C. Across regimens, mean Kt/Vs (1.5–1.6) and URRs (70%-73%) were comparable. No dialyzer was changed; 1 session was shortened 15 minutes because of circuit clot formation. Systemic argatroban clearance increased ∼20% during hemodialysis, without clinically significantly affecting ACTs. Upon argatroban discontinuation, ACTs and plasma argatroban decreased concurrently (elimination half-life, 35 ± 6 min). No thrombosis, bleeding, serious adverse events, or clinically significant changes in vital signs or routine laboratory measures occurred.ConclusionArgatroban, administered by each treatment regimen, provides safe, adequate anticoagulation to enable successful hemodialysis in ESRD patients. Argatroban dialytic clearance by high-flux membranes is clinically insignificant

Creating a Culture of Reading: Readers\u27 Advisory in the Academic Library

Readers\u27 advisory isn’t just for public and school libraries. Popular reading collections in academic libraries can support your patrons’ recreational reading needs and their curricular needs, as well. Topics to be discussed include the benefits and challenges of establishing these collections, undergraduate students’ expectations for offerings in popular fiction and nonfiction in academic libraries, getting your staff involved in working with and promoting these materials, developing local exhibits and book lists, formalizing your commitment to popular reading through your collection development policy, and more

Creating a Culture of Reading: Readers\u27 Advisory in the Academic Library

Readers\u27 advisory isn’t just for public and school libraries. Popular reading collections in academic libraries can support your patrons’ recreational reading needs and their curricular needs, as well. Topics to be discussed include the benefits and challenges of establishing these collections, undergraduate students’ expectations for offerings in popular fiction and nonfiction in academic libraries, getting your staff involved in working with and promoting these materials, developing local exhibits and book lists, formalizing your commitment to popular reading through your collection development policy, and more

Variants of the Adenosine A2A Receptor Gene Are Protective against Proliferative Diabetic Retinopathy in Patients with Type 1 Diabetes

AIMS: The adenosine A(2A) receptor (ADORA(2A)) may ameliorate deleterious physiologic effects associated with tissue injury in individuals with diabetes. We explored associations between variants of the ADORA(2A) gene and proliferative diabetic retinopathy (PDR) in a cohort of patients with type 1 diabetes (T1D). METHODS: The participants were from the Pittsburgh Epidemiology of Diabetes Complications prospective study of childhood-onset T1D. Stereoscopic photographs of the retinal fundus taken at baseline, then biennially, for 10 years were used to define PDR according to the modified Airlie House system. Two tagging single nucleotide polymorphisms (tSNPs; rs2236624-C/T and rs4822489-G/T) in the ADORA(2A) gene were selected using the HapMap (haplotype map) reference database. RESULTS: A significant association was observed between SNP rs2236624 and PDR in the recessive genetic model. Participants homozygous for the T allele displayed a decreased risk of developing prevalent PDR (odds ratio, OR = 0.36; p = 0.04) and incident PDR (hazard ratio = 0.156; p = 0.009), and for all cases of PDR combined (OR = 0.23; p = 0.001). The protective effect of T allele homozygosity remained after adjusting for covariates. Similarly, for SNP rs4822489, an association between PDR and T allele homozygosity was observed following covariate adjustment (OR = 0.55; 95% CI: 0.31–0.92; p = 0.04). CONCLUSION: Genetic variants of ADORA(2A) offer statistically significant protection against PDR development in patients with T1D

Zero Graffiti for a Beautiful City: The Cultural Politics of Urban Space in San Francisco

San Francisco, like many cities in the United States and across the world, has an official zero-tolerance policy on graffiti. In this article, we examine the academic literature concerned with graffiti and then present a case study of zero-tolerance abatement policies in San Francisco. Our analysis yields three main findings. First, zero-tolerance policy stimulates an anti-graffiti industry with vested interest in perpetuating an endless war for control of public space. Second, zero tolerance may generate an unintended result—the proliferation of tags and other forms of graffiti that people tend to dislike the most. Third, we find little evidence that the general public shares the same desire for zero tolerance as the San Francisco Government. Ultimately, we believe that more nuanced readings of graffiti allow greater numbers of people to make sensible, local, place-specific policies regarding graffiti

Palliative Care for Patients With Cancer: ASCO Guideline Update

PURPOSE: To provide evidence-based guidance to oncology clinicians, patients, nonprofessional caregivers, and palliative care clinicians to update the 2016 ASCO guideline on the integration of palliative care into standard oncology for all patients diagnosed with cancer. METHODS: ASCO convened an Expert Panel of medical, radiation, hematology-oncology, oncology nursing, palliative care, social work, ethics, advocacy, and psycho-oncology experts. The Panel conducted a literature search, including systematic reviews, meta-analyses, and randomized controlled trials published from 2015-2023. Outcomes of interest included quality of life (QOL), patient satisfaction, physical and psychological symptoms, survival, and caregiver burden. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 52 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the integration of palliative care in oncology. Oncology clinicians should refer patients with advanced solid tumors and hematologic malignancies to specialized interdisciplinary palliative care teams that provide outpatient and inpatient care beginning early in the course of the disease, alongside active treatment of their cancer. For patients with cancer with unaddressed physical, psychosocial, or spiritual distress, cancer care programs should provide dedicated specialist palliative care services complementing existing or emerging supportive care interventions. Oncology clinicians from across the interdisciplinary cancer care team may refer the caregivers (eg, family, chosen family, and friends) of patients with cancer to palliative care teams for additional support. The Expert Panel suggests early palliative care involvement, especially for patients with uncontrolled symptoms and QOL concerns. Clinicians caring for patients with solid tumors on phase I cancer trials may also refer them to specialist palliative care.Additional information is available at www.asco.org/supportive-care-guidelines